Guillaume Mathey

22PUBLICATIONS
84CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEpidemiological methodsPsychosocial aspects of childbirth and perinatal mental health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Aug 14, 2026
Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

|May 05, 2026
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

|Sep 04, 2025
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.

Antoine Gavoille, Mikail Nourredine, Fabien Rollot

|Aug 25, 2025
Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.

Guillaume Mathey, Jonathan Epstein, Tom Alix

|Jul 30, 2025
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.

Antoine Gavoille, Emmanuelle Leray, Romain Marignier

Pageof 4

Frequent Collaborators

9 joint publications

Jean-Philippe Camdessanché

8 joint publications

Elisabeth Maillart

8 joint publications

Jonathan Ciron

7 joint publications

Bertrand Bourre